Ticagrelor versus Clopidogrel in Acute Coronary Syndrome Patients with High Ischemic and Bleeding Risk after Drug-eluting Stent Implantation
Thrombosis and Haemostasis · 11.08.2026
DOI: 10.1055/a-2922-8191 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thrombosis and Haemostasis, online erschienen am 11.08.2026. Verfasst von Kun Na und 8 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Research Institute, General Hospital of Northern Theater Command, Department of Cardiology, Liaoning, China, Shenyang. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Liaoning Provincial Science and Technology Program Joint Program.
Abstract (Originalsprache)
Patients with acute coronary syndrome (ACS) who have concurrent high ischemic and high bleeding risk are common after percutaneous coronary intervention (PCI), yet evidence guiding P2Y12 inhibitor selection remains limited. We compared ticagrelor and clopidogrel in ACS patients meeting OPT-BIRISK dual high-risk criteria after drug-eluting stent (DES) implantation. We retrospectively analyzed a single-center PCI registry. ACS patients undergoing new-generation DES implantation (March 2019–March 2022) who met both high ischemic and high bleeding risk criteria were classified by discharge P2Y12 inhibitor. Propensity score overlap weighting was adjusted for confounding. The primary endpoint was 12-month net adverse clinical events (NACE): all-cause death, myocardial infarction, stroke, or Bleeding Academic Research Consortium (BARC) type 3 or 5 bleeding. The final cohort comprised 20,213 dual high-risk patients (ticagrelor, 4,563 [22.6%]; clopidogrel, 15,650 [77.4%]). NACE was similar between groups (4.58% vs. 5.21%; adjusted hazard ratio [aHR], 1.05; 95% confidence interval [CI], 0.89–1.23; p = 0.568). Ticagrelor was not associated with reduced ischemic events (aHR, 0.90; 95% CI, 0.72–1.12; p = 0.333) but with higher BARC type 3 or 5 bleeding (2.17% vs. 1.57%; aHR, 1.39; 95% CI, 1.08–1.77; p = 0.009). In exploratory subgroup analysis, ticagrelor was associated with higher NACE in patients aged 75 years or older (p-Value for interaction = 0.04). In dual high-risk ACS patients undergoing DES implantation, discharge ticagrelor-based dual antiplatelet therapy was associated with higher bleeding risk without reducing NACE or ischemic events compared with clopidogrel. These observational findings support individualized P2Y12 inhibitor selection and warrant prospective confirmation.
Autor:innen und Institutionen
- Cardiovascular Research Institute, General Hospital of Northern Theater Command, Department of Cardiology, Liaoning, China, Shenyang.
Förderung
- National Key Research and Development Program of China
- Liaoning Provincial Science and Technology Program Joint Program
Zitieren
APA
Na, K., Qiu, M., Zhang, T., Li, Y., Duan, Y., Li, Y., Li, J., Li, Y., & Han, Y. (2026). Ticagrelor versus Clopidogrel in Acute Coronary Syndrome Patients with High Ischemic and Bleeding Risk after Drug-eluting Stent Implantation. Thrombosis and Haemostasis. https://doi.org/10.1055/a-2922-8191
Vancouver
Na K, Qiu M, Zhang T, Li Y, Duan Y, Li Y, et al. Ticagrelor versus Clopidogrel in Acute Coronary Syndrome Patients with High Ischemic and Bleeding Risk after Drug-eluting Stent Implantation. Thrombosis and Haemostasis. 2026. doi:10.1055/a-2922-8191
BibTeX
@article{Na2026,
author = {Na, Kun and Qiu, Miaohan and Zhang, Tianai and Li, Yuying and Duan, Yixuan and Li, Yang and Li, Jing and Li, Yi and Han, Yaling},
title = {Ticagrelor versus Clopidogrel in Acute Coronary Syndrome Patients with High Ischemic and Bleeding Risk after Drug-eluting Stent Implantation},
journal = {Thrombosis and Haemostasis},
year = {2026},
doi = {10.1055/a-2922-8191}
}
EUVIMED